Quick Answer
Bluejay Diagnostics, Inc. reported Total Revenue of $249.0 thousand for fiscal year 2022.
Bluejay Diagnostics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | $249.0K | — | — |
| Net Income | -$6.85M +11.3% |
-$7.72M +22.5% |
-$9.95M -7.1% |
-$9.30M -166.5% |
-$3.49M -201.2% |
-$1.16M |
| Diluted EPS | -$15.25 +96.7% |
-$456.75 +87.4% |
-$3631.48 -39287.0% |
-$9.22 -2148.8% |
-$0.41 | — |
| Total Assets | $7.12M +6.9% |
$6.66M +36.7% |
$4.87M -64.0% |
$13.52M -35.7% |
$21.02M +1285.3% |
$1.52M |
| Cash and Equivalents | $5.16M +20.1% |
$4.30M +94.8% |
$2.21M -78.2% |
$10.11M -46.9% |
$19.05M +1987.7% |
$912.4K |
| Stockholders Equity | $5.98M +4.3% |
$5.73M +97.9% |
$2.89M -74.9% |
$11.54M -43.4% |
$20.38M +584.6% |
-$4.21M -43.4% |
| R&D Expense | $3.05M -12.2% |
$3.47M -39.2% |
$5.71M +37.6% |
$4.15M +261.7% |
$1.15M +117.7% |
$527.3K |
| Operating Income | -$6.95M +3.0% |
-$7.17M +30.5% |
-$10.31M -10.7% |
-$9.32M -188.5% |
-$3.23M -170.0% |
-$1.20M |
| Gross Profit | — | — | — | $48.9K | — | — |
| Shares Outstanding | 604,534 +336.5% |
138,503 +4370.7% |
3,098 -99.7% |
1.01M -95.0% |
20.11M +539.1% |
3.15M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | June 30, 2022 | $249.0K | — | — |
| Net Income | September 30, 2025 | -$1.60M | -7.8% | +18.3% |
| Diluted EPS | September 30, 2025 | -$1.01 | +98.7% | +28.4% |
| Total Assets | September 30, 2025 | $4.89M | -41.5% | -23.6% |
| Cash and Equivalents | September 30, 2025 | $3.08M | -46.4% | -30.6% |
| Stockholders Equity | September 30, 2025 | $3.69M | -48.5% | -30.2% |
| R&D Expense | September 30, 2025 | $785.6K | +42.4% | -11.7% |
| Operating Income | September 30, 2025 | -$1.62M | -18.8% | +18.6% |
| Gross Profit | June 30, 2022 | $48.9K | — | — |
| Shares Outstanding | September 30, 2025 | 1.64M | -90.8% | +9.7% |
- Bluejay Diagnostics, Inc. reported Total Revenue of $249.0 thousand for fiscal year 2022.
- Bluejay Diagnostics, Inc. reported Net Income of -$6.85 million for fiscal year 2025.
- Bluejay Diagnostics, Inc. showed an increase of +11.3% in Net Income compared to the prior fiscal year.
- Bluejay Diagnostics, Inc. reported Diluted EPS of $15.25 per share (loss) for fiscal year 2025.
- Bluejay Diagnostics, Inc. showed an increase of +96.7% in Diluted EPS compared to the prior fiscal year.
- Bluejay Diagnostics, Inc. reported Total Assets of $7.12 million for fiscal year 2025.
- Bluejay Diagnostics, Inc. showed an increase of +6.9% in Total Assets compared to the prior fiscal year.
- Bluejay Diagnostics, Inc. reported Cash and Equivalents of $5.16 million for fiscal year 2025.
- Bluejay Diagnostics, Inc. showed an increase of +20.1% in Cash and Equivalents compared to the prior fiscal year.
- Bluejay Diagnostics, Inc. reported Stockholders Equity of $5.98 million for fiscal year 2025.
- Bluejay Diagnostics, Inc. showed an increase of +4.3% in Stockholders Equity compared to the prior fiscal year.
- Bluejay Diagnostics, Inc. reported R&D Expense of $3.05 million for fiscal year 2025.
- Bluejay Diagnostics, Inc. showed a decrease of -12.2% in R&D Expense compared to the prior fiscal year.
- Bluejay Diagnostics, Inc. reported Operating Income of -$6.95 million for fiscal year 2025.
- Bluejay Diagnostics, Inc. showed an increase of +3.0% in Operating Income compared to the prior fiscal year.
- Bluejay Diagnostics, Inc. reported Gross Profit of $48.9 thousand for fiscal year 2022.
- Bluejay Diagnostics, Inc. reported Shares Outstanding of 604.5 thousand shares for fiscal year 2025.
- Bluejay Diagnostics, Inc. showed an increase of +336.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: